AgomAb Therapeutics (NASDAQ:AGMB) Research Coverage Started at Leerink Partners

Leerink Partners assumed coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research note released on Tuesday morning, Marketbeat.com reports. The firm issued an outperform rating and a $36.00 price target on the stock.

Other equities analysts have also recently issued reports about the stock. Wall Street Zen raised shares of AgomAb Therapeutics to a “hold” rating in a research note on Tuesday, February 17th. Morgan Stanley initiated coverage on shares of AgomAb Therapeutics in a report on Tuesday. They set an “overweight” rating and a $28.00 target price for the company. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, AgomAb Therapeutics currently has an average rating of “Buy” and a consensus price target of $32.00.

AgomAb Therapeutics Stock Down 3.2%

NASDAQ:AGMB opened at $14.21 on Tuesday. AgomAb Therapeutics has a 52-week low of $12.66 and a 52-week high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.